Onconetix Inc (ONCO)
Onconetix, Inc. is a Nasdaq-listed common stock issuer in the healthcare sector focused on biotechnology. The company develops and commercializes solutions for men’s health and oncology in the United States, the European Union, and other international markets. Its lead product is Proclarix, a blood-based diagnostic test used in the assessment of prostate cancer. Onconetix also has licensing arrangements with LabCorp related to the development and commercialization of Proclarix and other products, as well as with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. Founded in 2018 and headquartered in Cincinnati, Ohio, the company adopted the Onconetix name in December 2023 after previously operating as Blue Water Biotech, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ONCO
|
$1.16
|
30.2% Upside
|
Undervalued
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-0.4x
|
0.3x
|
5.0x
|
3.691 M
|
265.342 K
|
7.3%
|
100.0%
|
-44.6
|
—
|
97.7%
|
